Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.67 |
| ▸ | POLB | P06746 | 1/20 | 0.67 |
| ▸ | TSHR | P16473 | 3/20 | 0.56 |
| ▸ | CA1 | P00915 | 5/20 | 0.46 |
| ▸ | CA2 | P00918 | 3/20 | 0.43 |
| ▸ | CA9 | Q16790 | 3/20 | 0.43 |
| ▸ | CA7 | P43166 | 2/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | AGXT | P21549 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | TACR1 | P25103 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5375962 | 0.96 | KDM4E (0.67) | KDM4EPOLBTSHRCA1CA2 | |
| SCHEMBL3549969 | 0.96 | KDM4E (0.67) | KDM4EPOLBTSHRCA1CA2 | |
| SCHEMBL29705157 | 0.92 | KDM4E (0.62) | KDM4EPOLBTSHRCA1CA2 | |
| SCHEMBL18929793 | 0.91 | KDM4E (0.57) | KDM4EPOLBTSHRCA1CA2 | |
| SCHEMBL14672594 | 0.90 | KDM4E (0.56) | KDM4EPOLBTSHRCA1CA2 | |
| SCHEMBL10704165 | 0.89 | KDM4E (0.59) | KDM4EPOLBTSHRCA1CA2 | |
| SCHEMBL8352022 | 0.89 | KDM4E (0.59) | KDM4EPOLBTSHRCA1CA2 | |
| SCHEMBL22483593 | 0.89 | KDM4E (0.59) | KDM4EPOLBTSHRCA1CA2 | |
| SCHEMBL5375963 | 0.87 | TSHR (0.68) | KDM4EPOLBTSHRCA1CA2 | |
| SCHEMBL11146323 | 0.87 | TSHR (0.67) | KDM4EPOLBTSHRCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9352485-B2 | Dioxaborinanes and uses thereof | EMPIRE TECHNOLOGY DEVELOPMENT LLC (US) | 2016-05-31 | — | — | US | disclosed |
| US-9352485-B2 | Dioxaborinanes and uses thereof | EMPIRE TECHNOLOGY DEVELOPMENT LLC (US) | 2016-05-31 | — | — | US | disclosed |
| US-9352485-B2 | Dioxaborinanes and uses thereof | EMPIRE TECHNOLOGY DEVELOPMENT LLC (US) | 2016-05-31 | — | — | US | disclosed |
| US-9290598-B2 | Dioxaborinane co-polymers and uses thereof | EMPIRE TECHNOLOGY DEVELOPMENT LLC (US) | 2016-03-22 | — | — | US | disclosed |
| US-9095141-B2 | Antifouling compositions including dioxaborinanes and uses thereof | EMPIRE TECHNOLOGY DEVELOPMENT LLC (US) | 2015-08-04 | — | — | US | disclosed |
| US-9095141-B2 | Antifouling compositions including dioxaborinanes and uses thereof | EMPIRE TECHNOLOGY DEVELOPMENT LLC (US) | 2015-08-04 | — | — | US | disclosed |
| US-9095141-B2 | Antifouling compositions including dioxaborinanes and uses thereof | EMPIRE TECHNOLOGY DEVELOPMENT LLC (US) | 2015-08-04 | — | — | US | disclosed |
| US-20140037704-A1 | ANTIFOULING COMPOSITIONS INCLUDING DIOXABORINANES AND USES THEREOF | EMPIRE TECHNOLOGY DEVELOPMENT LLC (US) | 2014-02-06 | — | — | US | disclosed |
| US-20140037704-A1 | ANTIFOULING COMPOSITIONS INCLUDING DIOXABORINANES AND USES THEREOF | EMPIRE TECHNOLOGY DEVELOPMENT LLC (US) | 2014-02-06 | — | — | US | disclosed |
| WO-2014021852-A1 | ANTIFOULING COMPOSITIONS INCLUDING DIOXABORINANES AND USES THEREOF | EMPIRE TECHNOLOGY DEVELOPMENT LLC (US) | 2014-02-06 | — | — | WO | disclosed |
| US-8546617-B1 | Dioxaborinanes and uses thereof | EMPIRE TECHNOLOGY DEVELOPMENT LLC (US) | 2013-10-01 | — | — | US | disclosed |
| US-8546617-B1 | Dioxaborinanes and uses thereof | EMPIRE TECHNOLOGY DEVELOPMENT LLC (US) | 2013-10-01 | — | — | US | disclosed |
| US-20130252009-A1 | DIOXABORINANES AND USES THEREOF | CRESTLINE DIRECT FINANCE, L.P. | 2013-09-26 | — | — | US | disclosed |
| US-20130252009-A1 | DIOXABORINANES AND USES THEREOF | CRESTLINE DIRECT FINANCE, L.P. | 2013-09-26 | — | — | US | disclosed |
| WO-2013141875-A1 | DIOXABORINANES AND USES THEREOF | EMPIRE TECHNOLOGY DEVELOPMENT LLC (US) | 2013-09-26 | — | — | WO | disclosed |
| WO-2013141875-A1 | DIOXABORINANES AND USES THEREOF | EMPIRE TECHNOLOGY DEVELOPMENT LLC (US) | 2013-09-26 | — | — | WO | disclosed |
| US-20130252009-A1 | DIOXABORINANES AND USES THEREOF | CRESTLINE DIRECT FINANCE, L.P. | 2013-09-26 | — | — | US | disclosed |
| US-20100119508-A1 | PHENYLACETIC ACID INHIBITORS OF CYCLOOXYGENASE | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-05-13 | — | — | US | disclosed |
| EP-0607374-B1 | NOVEL CYCLIC LIPID DERIVATIVES AS POTENT PAF ANTAGONISTS | PO HANG IRON & STEEL (KR) | 1999-04-07 | — | — | EP | disclosed |
| US-4451509-A | WATERPROOF COATING FOR WOOD | BAYER AKTIENGESELLSCHAFT (DE) | 1984-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140037704-A1 | ANTIFOULING COMPOSITIONS INCLUDING DIOXABORINANES AND USES THEREOF | DSTN, DAD1, IDUA | KDM4E 2640/4885POLB 226/4885TSHR 1938/4885 |
| US-20130252009-A1 | DIOXABORINANES AND USES THEREOF | LOXL3, GLRX3, PRDX1 | KDM4E 3462/4885POLB 1594/4885TSHR 2543/4885 |
| US-20100119508-A1 | PHENYLACETIC ACID INHIBITORS OF CYCLOOXYGENASE | PTGS1, PTGES, PTGS2 | KDM4E 2673/4885POLB 2027/4885TSHR 3533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.